Download

Full Text

• The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993, 329:977-986. The Diabetes Control Complications Trial Research Group.
• Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA 2003, 290:2159-2167. The Diabetes Control Complications Trial Research EDIC Group.
• Trial Research Gro: Hypoglycemia in the Diabetes Control and Complications Trial. Diabetes 1997, 46:271-286. The Diabetes Control Complications.
• Influence of intensive diabetes treatment on quality-of-life outcomes in the diabetes control and complications trial. Diabetes Care 1996, 19:195-203. The Diabetes Control Complications Trial Research Gro.
• Rapaport R., Sills I.N. Implications of the DCCT for children and adolescents with IDDM. N J Med 1994, 91:227-228.
• Jeandidier N., Riveline J.P., Tubiana-Rufi N., Vambergue A., Catargi B., Melki V., et al. Treatment of diabetes mellitus using an external insulin pump in clinical practice. Diabetes Metab 2008, 34:425-438.
• Training in flexible, intensive insulin management to enable dietary freedom in people with Type 1 diabetes: dose adjustment for normal eating (DAFNE) randomized controlled trial. Diabet Med 2003, 20(Suppl 3):4-5. DAFNE Study Group.
• Bolli G.B., Andreoli A.M., Lucidi P. Optimizing the replacement of basal insulin in type 1 diabetes mellitus: no longer an elusive goal in the post-NPH era. Diabetes Technol Ther 2011, 13(Suppl 1):S43-S52.
• Chase H.P., Lockspeiser T., Peery B., Shepherd M., MacKenzie T., Anderson J., et al. The impact of the Diabetes Control and Complications Trial and Humalog insulin on glycohemoglobin levels and severe hypoglycemia in type 1 diabetes. Diabetes Care 2001, 24:430-434.
• Fagot-Campagna A., Fosse S.C.R. Caractéristiques, risque vasculaire et complications chez les personnes diabétiques en France métropolitaine: d'importantes évolutions entre Entred 2001 et Entred 2007. Bulletin Epidémiologique Hebdomadaire 2009, 450-454.
• The Effect of Continuous Glucose Monitoring in Well- Controlled Type 1 Diabetes. Diabetes Care 2009, 32:1378-1383. Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group.
• Cryer P.E., Davis S.N., Shamoon H. Hypoglycemia in Diabetes. Diabetes Care 2003, 26:1902-1912.
• Smith C.B., Choudhary P., Pernet A., Hopkins D., Amiel S.A. Hypoglycemia unawareness is associated with reduced adherence to therapeutic decisions in patients with type 1 diabetes. Diabetes Care 2009, 32:1196-1198.
• Prolonged nocturnal hypoglycemia is common during 12 months of continuous glucose monitoring in children and adults with type 1 diabetes. Diabetes Care 2010, 33:1004-1008. Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group.
• Cosson E., Hamo-Tchatchouang E., Dufaitre-Patouraux L., Attali J.R., Paries J., Schaepelynck-Belicar P. Multicentre, randomised, controlled study of the impact of continuous sub-cutaneous glucose monitoring (GlucoDay) on glycaemic control in type 1 and type 2 diabetes patients. Diabetes Metab 2009, 35:312-318.
• Ludvigsson J., Hanas R. Continuous subcutaneous glucose monitoring improved metabolic control in pediatric patients with type 1 diabetes: a controlled crossover study. Pediatrics 2003, 111:933-938.
• Chico A., Vidal-Rios P., Subira M., Novials A. The continuous glucose monitoring system is useful for detecting unrecognized hypoglycemias in patients with type 1 and type 2 diabetes but is not better than frequent capillary glucose measurements for improving metabolic control. Diabetes Care 2003, 26:1153-1157.
• Tanenberg R., Bode B., Lane W., Levetan C., Mestman J., Harmel A.P.T., et al. Use of the Continuous Glucose Monitoring System to guide therapy in patients with insulin-treated diabetes: a randomized controlled trial. Mayo Clin Proc 2004, 79:1521-1526.
• Hirsch I.B., Abelseth J., Bode B.W., Fischer J.S., Kaufman F.R., Mastrototaro J., et al. Sensor-augmented insulin pump therapy: results of the first randomized treat-to-target study. Diabetes Technol Ther 2008, 10:377-383.
• Wolpert H.A. The nuts and bolts of achieving end points with real-time continuous glucose monitoring. Diabetes Care 2008, 31(Suppl 2):S146-S149.
• Garg S.K., Voelmle M.K., Beatson C.R., Miller H.A., Crew L.B., Freson B.J., et al. Use of continuous glucose monitoring in subjects with type 1 diabetes on multiple daily injections versus continuous subcutaneous insulin infusion therapy. Diabetes Care 2011, 34:574-579.
• Bequette B.W. Continuous glucose monitoring: real-time algorithms for calibration, filtering, and alarms. J Diabetes Sci Technol 2010, 4:404-418.
• Deiss D., Bolinder J., Riveline J.-P., Battelino T., Bosi E., Tubiana-Rufi N., et al. Improved glycemic control in poorly controlled patients with type 1 diabetes using real-time continuous glucose monitoring. Diabetes Care 2006, 29:2730-2732.
• Continuous glucose monitoring and intensive treatment of type 1 diabetes. N Engl J Med 2008, 359:1464-1476. Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group.
• Raccah D., Sulmont V., Reznik Y., Guerci B., Renard E., Hanaire H., et al. Incremental value of continuous glucose monitoring when starting pump therapy in patients with poorly controlled type 1 diabetes. Diabetes Care 2009, 32:2245-2250.
• Bergenstal R.M., Tamborlane W.V., Ahmann A., Buse J.B., Dailey G., Davis S.N., et al. Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. N Engl J Med 2010, 363:311-320.
• Pickup J.C., Freeman S.C., Sutton A.J. Glycaemic control in type 1 diabetes during real time continuous glucose monitoring compared with self monitoring of blood glucose: meta-analysis of randomised controlled trials using individual patient data. BMJ 2011, 343:d3805.
• Langendam M.W., Luijf Y.M., Hooft L., Devries J.H., Mudde A.H., Scholten R.J. Continuous glucose monitoring systems for type 1 diabetes mellitus. Cochrane Database Syst Rev 2012, 1:CD008101.
• Sustained benefit of continuous glucose monitoring on A1c, glucose profiles, and hypoglycemia in adults with type 1 diabetes. Diabetes Care 2009, 32:2047-2049. Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group.
• Riveline J.P., Schaepelynck P., Chaillous L., Renard E., Sola-Gazagnes A., Penfornis A., et al. Assessment of patient-led or physician-driven continuous glucose monitoring in patients with poorly controlled type 1 diabetes using basal-bolus insulin regimens: A 1-year multicenter study. Diabetes Care 2012, 35:965-971.
• Bergenstal R.M., Tamborlane W.V., Ahmann A., Buse J.B., Dailey G., Davis S.N.J., et al. Sensor-augmented pump therapy for A1c reduction (STAR 3) study: results from the 6-month continuation phase. Diabetes Care 2011, 34:2403-2405.
• O'Connell M., Donath S., O'Neal D., Colman P., Ambler G., Jones T., et al. Glycaemic impact of patient-led use of sensor-guided pump therapy in type 1 diabetes: a randomised controlled trial. Diabetologia 2009, 52:1250-1257.
• Jenkins A.J., Krishnamurthy B., Best J.D., Cameron F.J., Colman P.G., Farish S., et al. Evaluation of an algorithm to guide patients with type 1 diabetes treated with continuous subcutaneous insulin infusion on how to respond to real-time continuous glucose levels. Diabetes Care 2010, 33:1242-1248.
• Hermanides J., Norgaard K., Bruttomesso D., Mathieu C., Frid A., Dayan C.M., et al. Sensor-augmented pump therapy lowers HbA(1c) in suboptimally controlled Type 1 diabetes; a randomized controlled trial. Diabet Med 2011, 28:1158-1167.
• Battelino T., Phillip M., Bratina N., Nimri R., Oskarsson P., Bolinder J. Effect of continuous glucose monitoring on hypoglycemia in type 1 diabetes. Diabetes Care 2011, 34:795-800.
• Radermecker R.P., Saint Remy A., Scheen A.J., Bringer J., Renard E. Continuous glucose monitoring reduces both hypoglycaemia and HbA1c in hypoglycaemia-prone type 1 diabetic patients treated with a portable pump. Diabetes Metab 2010, 36:409-413.
• Agrawal P., Welsh J.B., Kannard B., Askari S., Yang Q., Kaufman F.R. Usage and effectiveness of the low glucose suspend feature of the medtronic paradigm veo insulin pump. J Diabetes Sci Technol 2011, 5:1137-1141.
• Choudhary P., Shin J., Wang Y., Evans M.L., Hammond P.J., Kerr D., et al. Insulin pump therapy with automated insulin suspension in response to hypoglycemia: reduction in nocturnal hypoglycemia in those at greatest risk. Diabetes Care 2011, 34:2023-2025.
• Halford J., Harris C. Determining clinical and psychological benefits and barriers with continuous glucose monitoring therapy. Diabetes Technol Ther 2010, 12:201-205.
• Rubin R.R., Peyrot M. Treatment satisfaction and quality of life for an integrated continuous glucose monitoring/insulin pump system compared to self-monitoring plus an insulin pump. J Diabetes Sci Technol 2009, 3:1402-1410.
• Psychological aspects of continuous glucose monitoring in pediatric type 1 diabetes. Pediatr Diabetes 2006, 7:32-38. Diabetes Research in Children Network (DirecNet) Study Group.
• Cemeroglu A.P., Stone R., Kleis L., Racine M.S., Postellon D.C., Wood M.A. Use of a real-time continuous glucose monitoring system in children and young adults on insulin pump therapy: patients' and caregivers' perception of benefit. Pediatr Diabetes 2010, 11:182-187.
• Quality-of-Life Measures in Children and Adults With Type 1 Diabetes. Diabetes Care 2010, 33:2175-2177. Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group.
• Yogev Y., Chen R., Ben-Haroush A., Phillip M., Jovanovic L., Hod M. Continuous glucose monitoring for the evaluation of gravid women with type 1 diabetes mellitus. Obstet Gynecol 2003, 101:633-638.
• Chen R., Yogev Y., Ben-Haroush A., Jovanovic L., Hod M., Phillip M. Continuous glucose monitoring for the evaluation and improved control of gestational diabetes mellitus. J Matern Fetal Neonatal Med 2003, 14:256-260.
• Murphy H.R., Rayman G., Lewis K., Kelly S., Johal B., Duffield K., et al. Effectiveness of continuous glucose monitoring in pregnant women with diabetes: randomised clinical trial. BMJ 2008, 337.
• Kordonouri O., Pankowska E., Rami B., Kapellen T., Coutant R., Hartmann R., et al. Sensor-augmented pump therapy from the diagnosis of childhood type 1 diabetes: results of the Paediatric Onset Study (ONSET) after 12 months of treatment. Diabetologia 2010, 53:2487-2495.
• Mauras N., Beck R., Xing D., Ruedy K., Buckingham B., Tansey M., et al. A randomized clinical trial to assess the efficacy and safety of real-time continuous glucose monitoring in the management of type 1 diabetes in young children aged 4 to 10 years. Diabetes Care 2012, 35:204-210.
• Phillip M., Danne T., Shalitin S., Buckingham B., Laffel L., Tamborlane W., Battelino T. Use of continuous glucose monitoring in children and adolescents. Pediatr Diabetes 2012, 13:215-228.
• Battelino T., Conget I., Olsen B., Schütz-Fuhrmann I., Hommel L., Hoogma R., et al. Group SS: The SWITCH study: continuous glucose monitoring in type 1 diabetes. Pediatric Diabetes 2011, 12(suppl. 15):30.
• Chase H.P., Beck R.W., Xing D., Tamborlane W.V., Coffey J., Fox L.A., et al. Continuous glucose monitoring in youth with type 1 diabetes: 12-month follow-up of the Juvenile Diabetes Research Foundation continuous glucose monitoring randomized trial. Diabetes Technol Ther 2010, 12:507-515.
• Factors predictive of use and of benefit from continuous glucose monitoring in type 1 diabetes. Diabetes Care 2009, 32:1947-1953. Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group.
• McQueen R.B., Ellis S.L., Campbell J.D., Nair K.V., Sullivan P.W. Costeffectiveness of continuous glucose monitoring and intensive insulin therapy for type 1 diabetes. Cost Eff Resour Alloc 2011, 9:13.
• Huang E.S., O'Grady M., Basu A., Winn A., John P., Lee J., et al. Group Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group: the cost-effectiveness of continuous glucose monitoring in type 1 diabetes. Diabetes Care 2010, 33:1269-1274.
• Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40. BMJ 1998, 317:720-726. Group UKPDS.
• DeVries J.H. Continuous glucose monitoring: coming of age?. Eur J Endocrinol 2012, 166:1-4.
• Cobelli C., Renard E., Kovatchev B. Artificial pancreas: past, present, future. Diabetes 2011, 60:2672-2682.
• Kovatchev B., Cobelli C., Renard E., Anderson S., Breton M., Patek S., et al. Multinational study of subcutaneous model-predictive closed-loop control in type 1 diabetes mellitus: summary of the results. J Diabetes Sci Technol 2010, 4:1374-1381.
• Hovorka R., Allen J.M., Elleri D., Chassin L.J., Harris J., Xing D., et al. Manual closed-loop insulin delivery in children and adolescents with type 1 diabetes: a phase 2 randomised crossover trial. Lancet 2010, 375:743-751.
• Executive summary: standards of medical care in diabetes--2011. Diabetes Care 2011, 34(Suppl 1):S4-S10. Recommendations ADA.
• Blevins T.C., Bode B.W., Garg S.K., Grunberger G., Hirsch I.B., Jovanovic L., et al. Statement by the American Association of Clinical Endocrinologists Consensus Panel on continuous glucose monitoring. Endocr Pract 2010, 16:730-745.
• Hirsch I.B. Clinical review: Realistic expectations and practical use of continuous glucose monitoring for the endocrinologist. J Clin Endocrinol Metab 2009, 94:2232-2238.